Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference GlobeNewswire December 01, 2025 – Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting –– Actively Evaluating Strategy Across DLB and Alzheimer's Disease – PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cognition […]

Statement from Bart Demosky, Executive Vice President and CFO, Bombardier, on Moody's Ratings Upgrade to Ba3 from B1 GlobeNewswire December 01, 2025 MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — The Bombardier team is proud to share that Moody's has upgraded the company's credit rating from B1 to Ba3, with a positive outlook. With this recent

Stock Yards Bank & Trust announces Bowling Green Market President with deep community ties GlobeNewswire December 01, 2025 LOUISVILLE, Ky., Dec. 01, 2025 (GLOBE NEWSWIRE) — Rick Seadler has joined Stock Yards Bank & Trust as its Bowling Green Market President. Prior to joining the bank, Seadler served as the Regional President at Pinnacle Financial

Nexxen Announces November 2025 Share Repurchase Program Summary GlobeNewswire December 01, 2025 NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the Company repurchased 427,500 Ordinary Shares at an average price

North American Niobium and Critical Minerals Corp. Launches its C$2.69 Million District-Scale Fully-Funded Comprehensive 2026 Quebec Exploration Program Focused on Niobium and Rare Earth Elements Discoveries GlobeNewswire December 01, 2025 Vancouver, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium”

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification GlobeNewswire December 01, 2025 CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01,

Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 01, 2025 CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium Study findings to be featured in a poster spotlight presentation GlobeNewswire December 01, 2025 HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression. The ARCHER data

Post Holdings, Inc. (NYSE:POST) (the “Company” or “Post”) today announced it intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $1,300.0 million in aggregate principal amount of senior notes due 2036 (the “Notes”). The Notes will be unsecured, senior obligations of the Company and will be guaranteed by